Based on the Adverum Biotechnologies Inc stock forecast from 2 analysts, the average analyst target price for Adverum Biotechnologies Inc is USD 24.00 over the next 12 months. Adverum Biotechnologies Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adverum Biotechnologies Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Adverum Biotechnologies Inc’s stock price was USD 4.03. Adverum Biotechnologies Inc’s stock price has changed by -9.84% over the past week, -5.62% over the past month and -76.71% over the last year.
No recent analyst target price found for Adverum Biotechnologies Inc
No recent average analyst rating found for Adverum Biotechnologies Inc
Company Overview Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Read Less
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients...Read More
Frequently Asked Questions About Adverum Biotechnologies Inc (ADVM) Stock
Based on ratings from 2 analysts Adverum Biotechnologies Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ADVM's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ADVM is USD 24.00 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on ADVM's stock to indicate if its overvalued.
The last closing price of ADVM's stock was USD 4.03.
The most recent market capitalization for ADVM is USD 0.09B.
Based on targets from 2 analysts, the average taret price for ADVM is projected at USD 24.00 over the next 12 months.
This means that ADVM's stock price may go up by +495.53% over the next 12 months.
We can't find any ETFs which contains Adverum Biotechnologies Inc's stock.
As per our most recent records Adverum Biotechnologies Inc has 121 Employees.
Adverum Biotechnologies Inc's registered address is 100 Cardinal Way, Redwood City, CA, United States, 94063.
You can get more information about it from Adverum Biotechnologies Inc's website at https://adverum.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Adverum Biotechnologies Inc (ADVM) Stock
Based on ratings from 2 analysts Adverum Biotechnologies Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ADVM's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ADVM is USD 24.00 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on ADVM's stock to indicate if its overvalued.
The last closing price of ADVM's stock was USD 4.03.
The most recent market capitalization for ADVM is USD 0.09B.
Based on targets from 2 analysts, the average taret price for ADVM is projected at USD 24.00 over the next 12 months.
This means that ADVM's stock price may go up by +495.53% over the next 12 months.
We can't find any ETFs which contains Adverum Biotechnologies Inc's stock.
As per our most recent records Adverum Biotechnologies Inc has 121 Employees.
Adverum Biotechnologies Inc's registered address is 100 Cardinal Way, Redwood City, CA, United States, 94063.
You can get more information about it from Adverum Biotechnologies Inc's website at https://adverum.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADVM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
